BioXcel Therapeutics, Inc. — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
BioXcel Therapeutics executed the Fourteenth Amendment to its credit agreement dated August 24, 2026, adding a $1,250,000 Amendment No. 14 Term Loan from existing lenders (primarily Oaktree Capital funds and Qatar Investment Authority affiliate). Total facility increases from $202.3M to $203.6M. Key condition: borrower must execute definitive agreements for a transaction by August 31, 2026 that either pays debt in full or represents an acceptable alternative capital solution. Upfront fee is 20% of the new tranche commitment.
Why this rating
Modest debt increase ($1.25M ≈ 11.4% of $11M market cap) but urgent covenant requiring imminent transaction announcement signals acute distress. Company-scale material event.
Tradability signal
SHORT
conviction 39/100 · expected -0.80% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (13 in this cell) moved +2.34% in the called direction over 4 hrs; shrunk for sample size that's a +0.80% edge. Price is down 0.1% since the filing hit EDGAR — the slide has begun. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.77 ▲ 0.12% | at our read · backfill $0.77 | +10 min · backfill $0.77 ▲ 0.00% | +1 hr · backfill $0.78 ▲ 1.78% | +4 hrs · backfill $0.74 ▼ 4.21% |
The stock had already moved -0.12% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.